Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Moxetumomab pasudotox

EU orphan designation number: EU/3/13/1150   
Active ingredient: Moxetumomab pasudotox
Indication: Treatment of B-lymphoblastic leukaemia/lymphoma
Sponsor: MedImmune Ltd
Milstein Building, Granta Park, Great Abington, Cambridgeshire, CB21 6GH, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
02/08/2013 Orphan designation EMA/OD/024/13 (2013)4724 of 17/07/2013